Novo Nordisk's guidance cut and CEO resignation seen as a "double surprise": BMO

Novo Nordisk's stock plunged following a significant cut to its full-year sales and profit guidance, exacerbated by the CEO's resignation, which analysts termed a 'double surprise.' The guidance reduction is primarily attributed to 'multifaceted headwinds,' including lower-than-expected growth for key drugs Wegovy and Ozempic. Wegovy's performance was specifically impacted by increased compounding in the US and slower international market expansion amid competition, notably from Eli Lilly's tirzepatide, while Ozempic also faced heightened competitive pressures in the US. Despite these challenges, the prospect of a new, non-Danish CEO is seen by some as a potential catalyst to re-energize the company's strategy.

Analysis

Novo Nordisk is facing significant operational and strategic challenges, underscored by a dual shock of a full-year sales and profit guidance reduction and the CEO's resignation. BMO Capital Markets has characterized these events as a "double surprise," identifying multifaceted headwinds that are impacting the company's core growth drivers. Specifically, key products Wegovy (obesity) and Ozempic (diabetes) are experiencing lower-than-expected growth in the crucial U.S. market. Wegovy's underperformance is attributed to two primary factors: an increase in unregulated compounding within the U.S. and direct competitive pressure from Eli Lilly's tirzepatide, which is also contributing to slower international market expansion. Similarly, Ozempic's sales are being eroded by heightened competition, indicating that the pressure on Novo Nordisk's incretin portfolio is more severe than its management had anticipated. The only potential positive noted is the leadership transition, as an incoming non-Danish CEO could introduce a new global perspective to address the company's struggling strategy.

Key Decisions for Investors

• Given the lowered guidance, intensifying competition, and leadership uncertainty, investors should scrutinize Novo Nordisk's ability to defend market share for its key Wegovy and Ozempic franchises.
• The challenges faced by Novo Nordisk directly validate the competitive strength of Eli Lilly, suggesting investors could view LLY as a primary beneficiary of the shifting dynamics in the obesity and diabetes drug markets.
• Closely monitor the appointment of a new CEO and their initial strategic announcements, as this will be a critical indicator of the company's future direction and ability to counteract the identified headwinds.